The Evolution of Bloodstream Pathogen Testing

At BioFire, we know how important it is to stay ahead of changing multi-drug resistant organisms. That’s why BioFire developed the BioFire® Blood Culture Identification 2 (BCID2) Panel.* Now submitted to the Food and Drug Administration (FDA) for 510(k) clearance, the BioFire BCID2 Panel is more comprehensive than ever, testing for 43 targets—including bacteria, yeast, and antimicrobial resistance genes, all in a single test.

With enhanced coverage and optimized assays, the BioFire BCID2 Panel is the evolution of syndromic testing for bloodstream pathogens.

The existing BioFire® FilmArray® Blood Culture Identification (BCID) Panel, available since 2013, has changed lab workflow and patient management. It offers results in about an hour after positive blood culture, along with a menu of 27 targets. Faster results mean shortened time to optimal therapy.They also translate into a reduction in the use of broad-spectrum antibiotics2 and a reduction in healthcare costs.The BioFire BCID Panel has also been shown to enhance antimicrobial stewardship efforts.2

The next evolution, the BioFire BCID2 Panel, is more comprehensive than ever, detecting additional coagulase-negative Staphylococcus species, as well as emerging pathogens like Candida auris. The panel also features an MREJ assay that allows for more specific MRSA identification and 10 antimicrobial resistance genes to identify multi-drug resistant organisms.

With just two minutes hands-on time and complete results in about an hour after positive blood culture, the BioFire BCID2 Panel can provide fast, actionable results for the most common bloodstream pathogens.

*For investigational use only.

View the latest research on the
BioFire BCID2 Panel.

References:

  1. MacVane SH, Nolte FS. (2016) J Clin Microbiol. 54:2476-2484.
  2. Banerjee R, et al. (2015) Clin Iinfect D. 61(7):1071-1080.
  3. Pardo J, et al. (2016) Diagn Microbiol Infect Dis. 84(2):159–164.